United Kingdom-based DaltonTx has emerged from its development phase, announcing the completion of a £4 million seed financing round. This investment will fuel the company’s mission to develop advanced, AI-based discovery platforms. These platforms are designed to fundamentally change the financial aspects, timelines, and ultimate success rates of research and development, with the overarching goal of bringing life-changing medicines to patients much more quickly.
The pharmaceutical industry stands at a unique crossroads, with artificial intelligence offering an unprecedented opportunity to discover new medicines with greater effectiveness and efficiency. However, creating adaptive AI platforms is a complex endeavor that requires years of dedicated investment in sophisticated software engineering, combined with a profound understanding of scientific principles and technological advancements. DaltonTx directly addresses this challenge by offering a versatile platform that is not limited by specific diseases or technologies. This adaptive system seamlessly integrates into the existing workflows of pharmaceutical companies, biotechnology firms, and contract research organizations. This integration provides teams with immediate access to AI-enabled discovery capabilities, eliminating the need for these organizations to spend years developing such complex systems in-house.
At its core, DaltonTx is a company built by scientists, for scientists. Its approach goes far beyond simple predictive modeling, aiming to power the entire discovery process. This comprehensive involvement spans from the initial collection of raw data and model training, through the intricate stages of molecular design and synthesis, to crucial decision-making. DaltonTx’s platform is not merely predictive; it is truly adaptive. It functions as a reasoning engine that continuously learns from every scientist, every model, and every experiment conducted, leading to a steady improvement in outcomes over time.
The foundation of DaltonTx is built upon decades of practical, real-world experience. A distinguished team co-founded the company: Dr. Garry Pairaudeau, Adrian Rossall, Dr. Anthony Bradley, and Professor Charlotte Deane MBE. This group brings together an impressive blend of expertise in drug discovery, machine learning, and software engineering. Their collective experience includes developing pioneering AI discovery platforms at prominent organizations such as AstraZeneca and Exscientia, while also integrating world-leading academic research from the University of Oxford.
The DaltonTx platform has been specifically engineered to accommodate both small molecules and biologics, making it exceptionally well-suited to support even the most intricate research and development pipelines. And DaltonTx champions the concept of collaborative intelligence.
Scientists can actively engage with the system, merging their invaluable human expertise with an engine that continuously refines and learns. This synergistic approach ensures that human insight and machine learning work together in harmony, enhancing the overall discovery process.
KEY QUOTES:
“AI offers an opportunity to transform drug discovery, but it is still incredibly challenging for organisations to build their own capabilities. DaltonTx exists to change that. We are solving high-impact challenges with adaptive AI-enabled systems that integrate into scientific workflows, evolve with every experiment, and give organisations lasting AI capability.”
Dr. Garry Pairaudeau, Co-Founder of DaltonTx
“At DaltonTx, we’re generating biological and chemical insight that was previously out of reach. By combining cutting-edge machine learning with deep drug discovery expertise, we are creating technology that learns with every experiment and helps scientists turn ideas into impact.”
Professor Charlotte Deane MBE, Co-Founder of DaltonTx and Professor of Structural Bioinformatics at the University of Oxford
“DaltonTx is poised to become the intelligence backbone of drug discovery, providing scientific reasoning capabilities and deep integration into real drug discovery workflows. Led by a highly impressive team of industry experts, we believe the DaltonTx platform will soon be indispensable for every R&D organization across pharma, biotech, and CROs.”
Marc Moesser, Investment Manager at redalpine
“We are excited to back DaltonTx, a company poised to set a new standard in R&D execution. By combining world-class science with cutting-edge AI, the DaltonTx team is building the adaptive infrastructure that modern drug discovery needs,”
Mason Sinclair, Principal, IQ Capital
“What impressed us most about DaltonTx is the strength and depth of the founding team. Their unique combination of drug discovery, machine learning, and software engineering expertise positions them to lead the next generation of AI in pharma. We’re proud to back a team with the vision and execution capability to transform how medicines are discovered,”
Tom Wilson, Partner, Seedcamp
